

# Anal Cancer Therapeutic and Drug Pipeline Review H2

*Anal Cancer Treatment Pipeline Review  
H2 2017*

PUNE, INDIA, February 23, 2017

/EINPresswire.com/ -- Summary

The report provides comprehensive information on the therapeutics under development for [Anal Cancer](#), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects.



Wise Guy Reports business card. The card is blue with white text and features a stylized profile of a head made of dots. The text on the card includes: WISE GUY REPORTS, Norah Trent Partner Relations & Marketing Manager, sales@wiseguyreports.com, Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK), LinkedIn: https://www.linkedin.com/company/4828928, Twitter: https://twitter.com/WiseGuyReports, Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts, and the website Wise.Guy.

GET SAMPLE REPORT @ <https://www.wiseguyreports.com/sample-request/393587-anal-cancer-pipeline-review-h1-2016> □

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

## Scope

- The report provides a snapshot of the global therapeutic landscape of Anal Cancer
- The report reviews pipeline therapeutics for Anal Cancer by companies and

universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Anal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anal Cancer

#### Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anal Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

#### Table of Content: Key Points

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Anal Cancer Overview 7

Therapeutics Development 8

Pipeline Products for Anal Cancer - Overview 8

Pipeline Products for Anal Cancer - Comparative Analysis 9

Anal Cancer - Therapeutics under Development by Companies 10

Anal Cancer - Therapeutics under Investigation by Universities/Institutes 12

Anal Cancer - Pipeline Products Glance 13  
Clinical Stage Products 13  
Early Stage Products 14  
Anal Cancer - Products under Development by Companies 15  
Anal Cancer - Products under Investigation by Universities/Institutes 16  
Anal Cancer - Companies Involved in Therapeutics Development 17  
Advaxis, Inc. 17  
Amgen Inc. 18  
Eli Lilly and Company 19  
Gentical S.A. 20  
ISA Pharmaceuticals B.V. 21  
Novartis AG 22  
Oryx GmbH & Co. KG 23  
PDS Biotechnology Corporation 24  
Sun Pharma Advanced Research Company Ltd. 25  
Taiwan Liposome Company, Ltd. 26  
Anal Cancer - Therapeutics Assessment 27  
Assessment by Monotherapy Products 27  
Assessment by Target 28  
Assessment by Mechanism of Action 30  
Assessment by Route of Administration 32  
Assessment by Molecule Type 34  
Drug Profiles 36  
axalimogene filolisbac - Drug Profile 36  
...Continued

ACCESS REPORT @ <https://www.wiseguyreports.com/reports/393587-anal-cancer-pipeline-review-h1-2016>

Get in touch:

LinkedIn: [www.linkedin.com/company/4828928](http://www.linkedin.com/company/4828928)

Twitter: <https://twitter.com/WiseGuyReports> □

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/367898188>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.